A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)

Clinical trial NCT04636801 · TERMINATED

Trial details

NCT number: NCT04636801
Sponsor: Chiesi Farmaceutici S.p.A.
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Obstructive Pulmonary Disease

Start date: 2021-07-14
Primary completion: 2025-10-31
Enrollment: 4710

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.